Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
ACADIA Pharmaceuticals Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
ACAD
Nasdaq
2836
www.acadia.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for ACADIA Pharmaceuticals Inc.
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock
- Nov 12th, 2024 2:50 pm
ACADIA Pharmaceuticals Inc. Just Recorded A 43% EPS Beat: Here's What Analysts Are Forecasting Next
- Nov 9th, 2024 12:51 pm
ACADIA Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations
- Nov 8th, 2024 11:14 am
ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...
- Nov 7th, 2024 11:00 am
Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates
- Nov 6th, 2024 10:15 pm
Acadia: Q3 Earnings Snapshot
- Nov 6th, 2024 9:13 pm
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
- Nov 6th, 2024 9:05 pm
Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
- Nov 5th, 2024 9:05 pm
ACADIA Pharmaceuticals Inc (ACAD): Worst-Performing Growth Stock in 2024
- Oct 31st, 2024 6:22 pm
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
- Oct 17th, 2024 10:41 pm
Health Canada approves Acadia’s DAYBUE for Rett syndrome
- Oct 17th, 2024 11:28 am
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
- Oct 16th, 2024 8:07 pm
Are ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
- Oct 14th, 2024 10:55 am
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Oct 8th, 2024 8:05 pm
Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
- Sep 23rd, 2024 8:15 pm
High Growth Tech Stocks To Watch In September 2024
- Sep 3rd, 2024 10:02 am
Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options
- Aug 29th, 2024 12:30 pm
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
- Aug 28th, 2024 8:05 pm
Ryan Reynolds Announces More to Parkinson’s® Campaign
- Aug 14th, 2024 12:04 pm
Shareholders Can Be Confident That ACADIA Pharmaceuticals' (NASDAQ:ACAD) Earnings Are High Quality
- Aug 14th, 2024 10:47 am
Scroll